GC 1133A
Alternative Names: GC-1133ALatest Information Update: 12 Sep 2023
At a glance
- Originator GC Pharma
- Developer GC Biopharma
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mucopolysaccharidosis IV
Highest Development Phases
- Preclinical Mucopolysaccharidosis IV
Most Recent Events
- 31 Dec 2022 Preclinical trials in Mucopolysaccharidosis IV in South Korea (unspecified route) before December 2022
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 17 Jan 2022 GC 1133A is available for licensing as of 17 Jan 2022. http://www.globalgreencross.com/eng/research/collaboration.do (GC Pharma website, January 2022)